Mexico - Delayed Quote MXN

Moderna, Inc. (MRNA.MX)

520.00

0.00

(0.00%)

As of April 23 at 1:58:11 PM CST. Market Open.

Why vaccine makers aren't worried about Trump administration cuts

Vaccines have been a central focus for Trump's health leaders, but large-cap players aren't feeling the sting.

Yahoo Finance 20 hours ago

MRNA

MRK

SNY
3 Healthcare Stocks Facing Headwinds

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, and over the past six months, the industry has pulled back by 12.7%. This drop was worse than the S&P 500’s 7.5% loss.

StockStory 2 hours ago

MRNA

ZBH

TECH
Flagship’s latest venture reflects more than 25 years of leaping into the unknown

A new AI-based company launched by the prolific venture capital firm Flagship Pioneering marks another platform approach in forward-thinking early science.

Pharma Voice 8 hours ago

MRNA
Where Will Moderna Be in 5 Years?

In the early days of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) was a top performer, from both a share-price and an earnings perspective. As one of the leading coronavirus vaccine companies, the biotech brought in billions of dollars in annual earnings and saw its stock price jump more than 2,300% from January 2020 through early August of 2021. With demand for COVID vaccination on the decline, Moderna hasn't been able to count on its vaccine for growth.

Motley Fool 3 days ago

MRNA
Moderna (MRNA) Stock Drops Despite Market Gains: Important Facts to Note

Moderna (MRNA) reachead $24.73 at the closing of the latest trading day, reflecting a -1.85% change compared to its last close.

Zacks 6 days ago

MRNA
US Advisory Panel Votes To Expand Recommendation For Pfizer, GSK's RSV Vaccines For Older Adults Below 60 Years

On Wednesday, the Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of respiratory syncytial virus (RSV) vaccines approved for adults 50-59 years of age at increased risk of RSV-associated lower respiratory tract disease (LRTD). In June 2024, ACIP postponed a vote on a recommendation for adults aged 50-59 at increased risk for RSV-LRTD until additional data becomes available. The update includes Pfizer Inc.’s (NYSE:PFE) Abrysvo (Respiratory Syncyt

Benzinga 6 days ago

GSK

PFE

MRNA
Vaccine Stocks Rise on Growing Threat of Bird Flu Infections

The Biden administration is reportedly in talks with vaccine makers Moderna (MRNA) and Pfizer (PFE) to develop bird flu vaccines over increasing fears of widespread transmission of the infection.

Zacks 7 days ago

PFE

MRNA

CVAC
GSK & PFE's RSV Vaccines Recommended for Use in Adults Aged 50-59

The U.S. CDC's Advisory Committee recommends the use of GSK and Pfizer's RSV vaccines in adults aged 50-59 who are at high risk of severe RSV disease.

Zacks 7 days ago

PFE

MRNA
Bloom Energy, Rogers, 3D Systems, Moderna, and EchoStar Stocks Trade Down, What You Need To Know

A number of stocks fell in the afternoon session after Federal Reserve Chair Jerome Powell signaled a cautious stance on future monetary policy decisions during a speech in Chicago, emphasizing that trade tariffs could add upward pressure to inflation in the short term and complicate the Fed's efforts to stabilize the economy. He warned that such trade measures are "likely to move us further away from our goals," referring to the Fed's dual mandate of price stability and maximum employment.

StockStory 7 days ago

BE

MRNA

SATS
Unpacking Q4 Earnings: AbbVie (NYSE:ABBV) In The Context Of Other Therapeutics Stocks

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with AbbVie (NYSE:ABBV).

StockStory 8 days ago

ABBV

BMRN

MRNA
Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Zacks 10 days ago

THC

MRNA
Novavax slides after RFK Jr. casts doubts about COVID vaccine

Shares of Novavax (NVAX) are under pressure on Thursday following Robert F. Kennedy Jr.’s comments on the company’s COVID shot approval delay. The Secretary of Health and Human Services pointed to the vaccine’s single-antigen composition as the reason for the push back, adding that the FDA is “shifting our priorities to multiple-antigen vaccines.” SHIFTING PRIORITIES: The Food and Drug Administration is sitting on the decision to grant full approval for Novavax COVID-19 shot. In an interview wit

TipRanks 13 days ago

PFE

NVAX

MRNA
Trump Wants RFK Jr. To 'Go Wild' On Health Care. What This Means For Biotech Stocks.

Robert F. Kennedy Jr. is the new Health Secretary. From fluoride, vaccines and beef tallow, here's how he might "go wild" on biotech stocks.

Investor's Business Daily 13 days ago

LLY

BIIB

MRNA
Moderna to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

CAMBRIDGE, MA / ACCESS Newswire / April 10, 2025 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 1, 2025 to report its first quarter 2025 financial results, and provide ...

ACCESS Newswire 14 days ago

MRNA
PacBio (PACB) and Hims & Hers Health (HIMS), 10x Genomics (TXG), Moderna (MRNA) Shares Are Soaring, What You Need To Know

A number of stocks jumped in the afternoon session after markets rallied sharply on news that President Trump announced a 90-day tariff pause. Reciprocal tariffs were also dropped to 10% for most countries, sparking renewed optimism amid ongoing trade talks. The major stock indices rose as investors, growing impatient of seemingly irrational tariff actions, welcomed the pause as a sign of a more measured path forward.

StockStory 14 days ago

MRNA

TXG

PACB
Why Moderna Stock Was Down 31.8% in Q1 as the S&P 500 Had Its Worst Quarter Since 2022

The S&P 500 lost 4.6%, and the Nasdaq Composite lost 10.4%. Following the trend, shares of Moderna (NASDAQ: MRNA) slid 31.8% in the first three months of the year. More recently, the conspicuous exit of a top Food and Drug Administration (FDA) official has darkened investor sentiment.

Motley Fool 15 days ago

MRNA

^GSPC
Is Moderna, Inc. (MRNA) the Best Long Term Growth Stock to Buy According to Billionaires?

We recently published a list of 10 Best Long Term Growth Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against other best long term growth stocks to buy according to billionaires. As per Barclays, the US administration announced numerous executive orders with […]

Insider Monkey 15 days ago

MRNA
Moderna to Showcase Extensive Infectious Disease Research at ESCMID 2025

CAMBRIDGE, MA / ACCESS Newswire / April 7, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present research across multiple infectious disease areas, including COVID-19, influenza, respiratory syncytial virus (RSV), cytomegalovirus ...

ACCESS Newswire 17 days ago

MRNA
Spotting Winners: United Therapeutics (NASDAQ:UTHR) And Therapeutics Stocks In Q4

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with United Therapeutics (NASDAQ:UTHR).

StockStory 17 days ago

UTHR

BMRN

MRNA
Moderna (NasdaqGS:MRNA) Declines 19% Over A Week Amid Market Volatility

Moderna (NasdaqGS:MRNA) experienced a significant decline of 19% over the past week. This drop can largely be attributed to broader market turbulence, amplified by the steep fall in major indices such as the Dow, S&P 500, and Nasdaq, which collectively entered into correction or bear market territories due to escalating trade tensions and tariff uncertainties. As a biotechnology company, Moderna shares may have faced additional pressures amidst general concerns about economic growth and...

Simply Wall St. 17 days ago

MRNA

Performance Overview

Return	MRNA.MX	S&P 500 (^GSPC)
YTD	-39.25%	-7.41%
1-Year	-71.58%	+7.38%
3-Year	-81.88%	+27.48%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Moderna, Inc. (MRNA.MX)

Why vaccine makers aren't worried about Trump administration cuts

3 Healthcare Stocks Facing Headwinds

Flagship’s latest venture reflects more than 25 years of leaping into the unknown

Where Will Moderna Be in 5 Years?

Moderna (MRNA) Stock Drops Despite Market Gains: Important Facts to Note

US Advisory Panel Votes To Expand Recommendation For Pfizer, GSK's RSV Vaccines For Older Adults Below 60 Years

Vaccine Stocks Rise on Growing Threat of Bird Flu Infections

GSK & PFE's RSV Vaccines Recommended for Use in Adults Aged 50-59

Bloom Energy, Rogers, 3D Systems, Moderna, and EchoStar Stocks Trade Down, What You Need To Know

Unpacking Q4 Earnings: AbbVie (NYSE:ABBV) In The Context Of Other Therapeutics Stocks

Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings

Novavax slides after RFK Jr. casts doubts about COVID vaccine

Trump Wants RFK Jr. To 'Go Wild' On Health Care. What This Means For Biotech Stocks.

Moderna to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

PacBio (PACB) and Hims & Hers Health (HIMS), 10x Genomics (TXG), Moderna (MRNA) Shares Are Soaring, What You Need To Know

Why Moderna Stock Was Down 31.8% in Q1 as the S&P 500 Had Its Worst Quarter Since 2022

Is Moderna, Inc. (MRNA) the Best Long Term Growth Stock to Buy According to Billionaires?

Moderna to Showcase Extensive Infectious Disease Research at ESCMID 2025

Spotting Winners: United Therapeutics (NASDAQ:UTHR) And Therapeutics Stocks In Q4

Moderna (NasdaqGS:MRNA) Declines 19% Over A Week Amid Market Volatility

Performance Overview